%0 Journal Article
%T Shoring Up Osteoporosis Management: A Fresh Start?
%A Furr N
%A Ulmer A
%A Cardon B
%J J Am Board Fam Med
%V 37
%N 3
%D 2024 May-Jun
%M 39142871
%F 2.395
%R 10.3122/jabfm.2024.240060R0
%X Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.